{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:18:12Z","timestamp":1760059092196,"version":"build-2065373602"},"reference-count":106,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioTech"],"abstract":"<jats:p>As part of the substantial public discourse surrounding the distribution and use of mifepristone, which is used with misoprostol to facilitate drug-induced abortions, claims comparing the safety of this regimen to that of common pharmaceuticals have emerged and proliferated. Offered in forums ranging from social media to the Supreme Court, these claims have so gained public acceptance that they are now echoed without scrutiny and, at times, reference. Yet the simplistic slogan that \u201cmifepristone is safer than Tylenol\u201d, though easily disseminated, defies both an intuitive understanding of how we evaluate drug safety and our norms and regulations for doing so. Indeed, if such an assertion was attributable to the manufacturer, it would precipitate a reprimand by the FDA given the lack of specific, controlled, and head-to-head evidence rightly required for its support. To the extent that these claims persist, however, including among the outputs of medical societies, abortion centers, clinical researchers, and government officials, and to the extent that they aim to inform both individual and public decision-making, it is critical that the evidence offered for their support be thoroughly explored. Such examination reveals these claims to be wholly unfounded, offering deficient and disingenuous representations of safety for any of the drugs compared.<\/jats:p>","DOI":"10.3390\/biotech14020039","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T20:26:50Z","timestamp":1748204810000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Origins and Proliferation of Unfounded Comparisons Regarding the Safety of Mifepristone"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-9278","authenticated-orcid":false,"given":"Cameron","family":"Louttit","sequence":"first","affiliation":[{"name":"Charlotte Lozier Institute, Arlington, VA 22206, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"ref_1","unstructured":"Jones, R.K., and Friedrich-Karnik, A. (2024). Medication Abortion Accounted for 63% of All US Abortions in 2023\u2014An Increase from 53% in 2020, Guttmacher Institute. Available online: https:\/\/www.guttmacher.org\/2024\/03\/medication-abortion-accounted-63-all-us-abortions-2023-increase-53-2020."},{"key":"ref_2","unstructured":"(2025, May 22). Teen\u2019s Death Rekindles Abortion Pill Battle. Chicago Tribune, Available online: https:\/\/www.chicagotribune.com\/2003\/11\/30\/teens-death-rekindles-abortion-pill-battle\/."},{"key":"ref_3","unstructured":"Szabo, L. (2025, May 22). How the Supreme Court\u2019s Mifepristone Ruling Could Affect Abortion Access and Future Drug Approvals. Available online: https:\/\/www.scientificamerican.com\/article\/how-the-supreme-courts-mifepristone-ruling-could-affect-abortion-access-and\/."},{"key":"ref_4","unstructured":"Schmidt, E. (2025, May 22). The Fight over Medical Abortion Has Worsened Pregnancy Care. Available online: https:\/\/www.statnews.com\/2024\/06\/13\/supreme-court-fight-mifepristone-worsened-pregnancy-care\/."},{"key":"ref_5","unstructured":"Grant, R., and Gold, E.I. (2025, May 22). Where to Find the Abortion Pill and What to Expect. Available online: https:\/\/www.thecut.com\/article\/find-abortion-pill-what-to-expect.html."},{"key":"ref_6","unstructured":"Koons, C. (2025, May 22). Abortion Pill Mifepristone Is Safer Than Tylenol and Almost Impossible to Get. Available online: https:\/\/www.bloomberg.com\/news\/features\/2022-02-17\/abortion-pill-mifepristone-is-safer-than-tylenol-and-almost-impossible-to-get."},{"key":"ref_7","unstructured":"Choi, A., and Mullery, W. (2025, May 22). How Safe Is the Abortion Pill Compared with Other Common Drugs?. Available online: https:\/\/www.cnn.com\/health\/abortion-pill-safety-dg\/index.html."},{"key":"ref_8","unstructured":"Baker, C.N. (2025, May 22). Abortion Pills in Your Medicine Cabinet? Advance Provision Medication to End Early Pregnancies. Available online: https:\/\/msmagazine.com\/2021\/12\/14\/abortion-pill-end-early-pregnancy-at-home\/."},{"key":"ref_9","unstructured":"Hill, A., and Rodriguez, K. (2025, May 22). Abortion Pill Restricted by FDA Record Safer than Penicillin, Viagra. Available online: https:\/\/www.usatoday.com\/story\/news\/2020\/07\/10\/abortion-pill-restricted-fda-record-safer-than-penicillin-viagra\/5412810002\/."},{"key":"ref_10","unstructured":"Fernando, C. (2025, May 22). Mifepristone \u2018Safer Than Tylenol\u2019, Experts Say Amid Court Battle over Major Abortion Pill. Available online: https:\/\/www.usatoday.com\/story\/news\/nation\/2023\/04\/18\/mifepristone-case-abortion-pill-drug-tyenol-fda\/11687403002\/."},{"key":"ref_11","unstructured":"Cauterucci, C. (2025, May 22). Mifepristone Ban: You Will Still Be Able to Get a Medication Abortion\u2014Even If This Inhumane Ruling out of Texas Stands. Available online: https:\/\/slate.com\/news-and-politics\/2023\/04\/mifepristone-ban-medication-abortion-still-available.html."},{"key":"ref_12","unstructured":"Demirhan, A. (2025, May 22). The Same Dark Money Groups that Helped Overturn Roe Are Also Behind Attacks on Abortion Pill. Available online: https:\/\/msmagazine.com\/2023\/02\/06\/fda-abortion-pills\/."},{"key":"ref_13","unstructured":"Noor, P. (2025, May 22). How Mifepristone Became a Target of the US Anti-Abortion Movement. Available online: https:\/\/www.theguardian.com\/world\/2023\/may\/16\/how-mifepristone-became-a-target-of-the-us-anti-abortion-movement."},{"key":"ref_14","unstructured":"Phillips, A. (2025, May 22). Texas Judge\u2019s Mifepristone Ruling Questioned by Doctors. Available online: https:\/\/www.newsweek.com\/texas-judge-mifepristone-abortion-pill-ruling-questioned-doctors-1793289."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.contraception.2003.11.016","article-title":"Presenting Health Risks Honestly: Mifepristone, a Case in Point","volume":"69","author":"Stewart","year":"2004","journal-title":"Contraception"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/GCO.0000000000000585","article-title":"Self-Managed Abortion","volume":"31","author":"Conti","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMp1908305","article-title":"Time to Reevaluate U.S. Mifepristone Restrictions","volume":"381","author":"Henney","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s11606-020-05836-9","article-title":"Medication to Manage Abortion and Miscarriage","volume":"35","author":"Beaman","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_19","first-page":"171","article-title":"Self-Managed Abortion in Africa","volume":"25","author":"Pizzarossa","year":"2023","journal-title":"Health Hum. Rights"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/M23-0981","article-title":"Science v. Ideology in Court: Mifepristone and the U.S. Food and Drug Administration","volume":"176","author":"Mariner","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_21","unstructured":"(2025, May 22). Analysis of Medication Abortion Risk and the FDA Report \u201cMifepristone US Post-Marketing Adverse Events Summary Through 12\/31\/2022\u201d. Available online: https:\/\/www.ansirh.org\/sites\/default\/files\/2024-05\/Analysis%20of%20MA%20Risk%20and%20FDA%20Report%20Issue%20Brief%20FINAL.pdf."},{"key":"ref_22","unstructured":"(2025, May 22). Safety and Effectiveness of First-Trimester Medication Abortion in the United States. Available online: https:\/\/www.ansirh.org\/sites\/default\/files\/publications\/files\/medication-abortion-safety.pdf."},{"key":"ref_23","unstructured":"Phillips, K. (2025, May 22). Medication Abortion Pills Are Safer than Viagra, Penicillin, & Acetaminophen (Tylenol). Available online: https:\/\/www.chatstudy.org\/post\/medication-abortion-pills-are-safer-than-viagra-penicillin-acetaminophen-tylenol."},{"key":"ref_24","unstructured":"(2025, May 22). Motion for Summary Judgment by All Plaintiffs, Washington v. FDA, No. 23-3026 (E.D. Wash 2024). Available online: https:\/\/www.doj.state.or.us\/wp-content\/uploads\/2024\/10\/156_MotionforSummaryJudgment.pdf."},{"key":"ref_25","unstructured":"(2025, May 22). Whole Woman\u2019s Health All. v. FDA, No. 3:23-Cv-00019, 2023 WL 5401885 (W.D. Va. 2023). Available online: https:\/\/storage.courtlistener.com\/recap\/gov.uscourts.vawd.128384\/gov.uscourts.vawd.128384.1.0.pdf."},{"key":"ref_26","unstructured":"(2025, May 22). Brief of Over 200 Reproductive Health, Rights, and Justice Organizations as Amici Curiae, Danco Labs v. All. Hippocratic Med., No. 22A901, 143 S. Ct. 1075 (2023). Available online: https:\/\/www.aclu.org\/cases\/danco-laboratories-llc-v-alliance-for-hippocratic-medicine-u-s-fda-v-alliance-for-hippocratic-medicine?document=Brief-amici-curiae-of-Over-200-Reproductive-Health-Rights-and-Justice-Organizations."},{"key":"ref_27","unstructured":"(2025, May 22). Brief of Appellant, Trust Women Found. v. Bennett, 2022 WL 1597011 (Kan. Ct. App. 2022). Available online: https:\/\/reproductiverights.org\/wp-content\/uploads\/2020\/12\/Trust-Women-Foundation-v.-Bennett-Brief-of-Appellant.pdf."},{"key":"ref_28","unstructured":"(2025, May 22). Brief of Doctors for America and the Reproductive Health Coalition as Amici Curiae, FDA v. AHM, 602 U.S. 367 (2024), Available online: https:\/\/www.supremecourt.gov\/DocketPDF\/23\/23-235\/284849\/20231012141543308_23-235_Amici%20Brief.pdf."},{"key":"ref_29","unstructured":"(2025, May 22). Brief of Amici Curiae Medical and Public Health Societies, AHM v. FDA, 668 F. Supp. 3d 507 (N.D. Tex. 2023). Available online: https:\/\/storage.courtlistener.com\/recap\/gov.uscourts.txnd.370067\/gov.uscourts.txnd.370067.91.1.pdf."},{"key":"ref_30","unstructured":"Office of the Attorney General of Connecticut (2025, May 22). Attorney General Tong Urges Federal Judge to Unravel Restrictions on Mifepristone, Available online: https:\/\/portal.ct.gov\/ag\/press-releases\/2024-press-releases\/attorney-general-tong-urges-federal-judge-to-unravel-restrictions-on-mifepristone."},{"key":"ref_31","unstructured":"Executive Office of the Governor of Michigan (2025, May 22). Governor Whitmer Statement as US Supreme Court Hears Case Weighing Access to Mifepristone, Available online: https:\/\/www.michigan.gov\/whitmer\/news\/press-releases\/2024\/03\/26\/governor-whitmer-statement-as-us-supreme-court-hears-case-weighing-access-to-mifepristone."},{"key":"ref_32","unstructured":"Office of the Attorney General of Maine (2025, May 22). Maine Joins FDA Suit over Unlawful, Unnecessary Restrictions on Medication Abortion Drug, Available online: https:\/\/www.maine.gov\/ag\/news\/article.shtml?id=10582678."},{"key":"ref_33","unstructured":"Office of Congresswoman Ayanna Pressley (2025, May 22). WATCH: Pressley Plays \u2018Fact or Fiction\u2019 with FDA Commissioner, Affirms Safety of Mifepristone, Available online: https:\/\/pressley.house.gov\/2024\/04\/11\/watch-pressley-plays-fact-or-fiction-with-fda-commissioner-affirms-safety-of-mifepristone\/."},{"key":"ref_34","unstructured":"(2025, May 22). Maura Healey on Instagram: \u201cMifepristone Is Safer than Tylenol, Penicillin, and Viagra. Attacks on Medication Abortion Have Never Been About Protecting Women\u2019s Health. They\u2019re About Controlling Women\u2019s Bodies. Massachusetts Won\u2019t Stand for It\u201d. Available online: https:\/\/www.instagram.com\/reel\/C5CDHuoPGNZ\/."},{"key":"ref_35","unstructured":"(2025, May 22). Congressman Dan Goldman on Instagram: \u201cMifepristone Is Safer than Tylenol and Accounts for over 50% of Abortions in the U.S. but in His Never-Ending Quest to Control Women, Trump\u2019s Project 2025 Targets Abortion Medication and Further Endangers Women. We Must Ensure Medication Abortion Remains Widely Available\u201d. Available online: https:\/\/www.instagram.com\/reel\/DAQ7BwvuhSx\/."},{"key":"ref_36","unstructured":"Ron Wyden [@RonWyden] (2025, May 22). That\u2019s Actually a Lie Peddled by Right-Wing Extremists and Mifepristone Is Safer than Tylenol. Hope This Helps!. Available online: https:\/\/x.com\/RonWyden\/status\/1772683554721317062."},{"key":"ref_37","unstructured":"State of Nevada Office of the Attorney General (2025, May 22). Biennial Report 2022-2024, Available online: https:\/\/ag.nv.gov\/uploadedFiles\/agnvgov\/Content\/Issues\/Attorney%20General%20Biennial%20Report%202022-2024.pdf."},{"key":"ref_38","unstructured":"Rep (2025, May 22). Jacobs Calls Texas Judge\u2019s Order to Ban Abortion Pill \u201cMisogynistic Attack\u201d. Available online: https:\/\/timesofsandiego.com\/politics\/2023\/04\/07\/rep-jacobs-calls-texas-judges-order-to-ban-abortion-pill-misogynistic-attack\/."},{"key":"ref_39","unstructured":"Office of Congressman Daniel Goldman (2025, May 22). Congressman Dan Goldman, Congresswoman Judy Chu Again Urge Pharmacies to Obtain Certification to Distribute Medication Abortion Following Supreme Court Decision, Available online: http:\/\/goldman.house.gov\/media\/press-releases\/congressman-dan-goldman-congresswoman-judy-chu-again-urge-pharmacies-obtain."},{"key":"ref_40","unstructured":"Plan C Pills (2025, May 22). Abortion Pills: An Overview. Available online: https:\/\/www.plancpills.org\/resource-library."},{"key":"ref_41","unstructured":"carafem (2025, May 22). 10 Things Riskier Than Abortion: Is Abortion Safe?. Available online: https:\/\/carafem.org\/learn-more\/blog\/10-things-riskier-than-abortion."},{"key":"ref_42","unstructured":"Hey Jane (2025, May 22). Maine Abortion Cost and How to Get One. Available online: https:\/\/www.heyjane.com\/cost-of-abortion\/maine."},{"key":"ref_43","unstructured":"Women on Waves (2025, May 22). Is a Medical Abortion Dangerous?. Available online: https:\/\/www.womenonwaves.org\/en\/page\/3333\/is-a-medical-abortion-dangerous."},{"key":"ref_44","unstructured":"National Women\u2019s Health Network (2025, May 22). Health Facts: Abortion with Pills. Available online: https:\/\/web.archive.org\/web\/20200612121653\/https:\/nwhn.org\/abortion-pills-medication-abortion\/."},{"key":"ref_45","unstructured":"Planned Parenthood (2025, May 22). How Safe Is the Abortion Pill?. Available online: https:\/\/www.plannedparenthood.org\/learn\/abortion\/the-abortion-pill\/how-safe-is-the-abortion-pill."},{"key":"ref_46","unstructured":"(2025, May 22). Frequently Asked Questions about Fatal Infection and Mifepristone Medical Abortion. Available online: https:\/\/gynuity.org\/assets\/resources\/factsht_technicalfatalinfectionma_en.pdf."},{"key":"ref_47","unstructured":"(2025, May 22). IND Content and Format; 21 CFR \u00a7 312.23(a), Available online: https:\/\/www.ecfr.gov\/current\/title-21\/part-312\/section-312.23#p-312.23(a)."},{"key":"ref_48","unstructured":"(2025, May 22). Content and Format of an NDA; 21 CFR \u00a7 314.50(d), Available online: https:\/\/www.ecfr.gov\/current\/title-21\/part-314\/section-314.50#p-314.50(d)."},{"key":"ref_49","unstructured":"(2025, May 22). Prescription-Drug Advertisements; 21 CFR \u00a7 202.1(e), Available online: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-202\/section-202.1."},{"key":"ref_50","unstructured":"Reeves, N., Lundy, S.H., Ba\u00f1uelos, H., and Russell, G. (2025, May 22). The Legal 500 Country Comparative Guides: United States Pharmaceutical Advertising. Available online: https:\/\/www.kslaw.com\/attachments\/000\/011\/319\/original\/The_Legal_500_Country_Comparative_Guides_-_United_States_Pharmaceutical_Advertising.pdf?1702050651."},{"key":"ref_51","unstructured":"(2025, May 22). Analysis of Medication Abortion Risk and the FDA Report \u201cMifepristone U.S. Post-Marketing Adverse Events Summary through 12\/31\/2018\u201d. Available online: https:\/\/www.ansirh.org\/sites\/default\/files\/publications\/files\/mifepristone_safety_4-23-2019.pdf."},{"key":"ref_52","unstructured":"(2025, May 22). Analysis of Medication Abortion Risk and the FDA Report \u201cMifepristone US Post-Marketing Adverse Events Summary through 6\/30\/2021\u201d. Available online: https:\/\/www.ansirh.org\/sites\/default\/files\/2022-11\/mifepristone_safety_11-15-22_Updated_0.pdf."},{"key":"ref_53","unstructured":"(2025, May 22). Case Backgrounder: U.S. Food & Drug Administration; et al. v. Alliance for Hippocratic Medicine, et al. 2024. Center for Reproductive Rights. Available online: https:\/\/reproductiverights.org\/wp-content\/uploads\/2024\/04\/FDA-v.-AHM-Case-Backgrounder-new-6-13-24.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40264-017-0611-5","article-title":"Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System","volume":"41","author":"Min","year":"2018","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e2419823","DOI":"10.1001\/jamanetworkopen.2024.19823","article-title":"Access and Safety\u2014The FDA Drug Approval Conundrum","volume":"7","author":"Good","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_57","unstructured":"(2025, May 22). MIFEPREX Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020687s020lbl.pdf."},{"key":"ref_58","unstructured":"(2025, May 22). Risk Evaluation and Mitigation Strategy (REMS) Single Shared System for Mifepristone 200 Mg, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Mifepristone_2023_03_23_REMS_Full.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/JMDH.S399209","article-title":"\u201cOut of This World\u201d: Norwegian Women\u2019s Experiences of Medical Abortion Pain","volume":"16","author":"Lyberg","year":"2023","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/bmjsrh-2024-202533","article-title":"Expectations and Experiences of Pain during Medical Abortion at Home: A Secondary, Mixed-Methods Analysis of a Patient Survey in England and Wales","volume":"51","author":"McCulloch","year":"2024","journal-title":"BMJ Sex. Reprod. Health"},{"key":"ref_61","unstructured":"Walker, A.S., Corum, J., Khurana, M., and Wu, A. (2025, May 22). Are Abortion Pills Safe? Here\u2019s the Evidence. Available online: https:\/\/www.nytimes.com\/interactive\/2023\/04\/01\/health\/abortion-pill-safety.html."},{"key":"ref_62","unstructured":"Karlis, N. (2025, May 22). Yes, Some Medication Abortion Patients Go to the ER\u2014But It May Not Be for What You Think. Available online: https:\/\/www.salon.com\/2024\/03\/20\/yes-some-medication-abortion-patients-go-to-the-er--but-it-may-not-be-for-what-you-think\/."},{"key":"ref_63","unstructured":"(2025, May 22). Mifepristone Patient Agreement Form, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Mifepristone_2023_01_03_Patient_Agreement_Form.pdf."},{"key":"ref_64","unstructured":"Mifepristone, U.S. (2025, May 22). Mifepristone U.S. Post-Marketing Adverse Events Summary Through 12\/31\/2022, Available online: https:\/\/www.fda.gov\/media\/164331\/download."},{"key":"ref_65","unstructured":"(2025, May 22). Patterns of Medication Use in the United States: A Report from the Slone Survey. Available online: https:\/\/www.bu.edu\/slone\/files\/2012\/11\/SloneSurveyReport2006.pdf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/15563650903232345","article-title":"The FDA Acetaminophen Advisory Committee Meeting\u2014What Is the Future of Acetaminophen in the United States? The Perspective of a Committee Member","volume":"47","author":"Krenzelok","year":"2009","journal-title":"Clin. Toxicol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/pds.1191","article-title":"Estimates of Acetaminophen (Paracetomal)-associated Overdoses in the United States","volume":"15","author":"Nourjah","year":"2006","journal-title":"Pharmacoepidemiol. Drug"},{"key":"ref_68","unstructured":"U.S. Food and Drug Administration (2025, May 22). FDA Adverse Events Reporting System (FAERS) Public Dashboard\u2014Frequently Asked Questions, Available online: https:\/\/fis.fda.gov\/extensions\/FPD-FAQ\/FPD-FAQ.html#_Toc514144622."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archinte.161.1.15","article-title":"Anaphylaxis in the United States: An Investigation into Its Epidemiology","volume":"161","author":"Neugut","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"ref_70","first-page":"159","article-title":"Nature and Extent of Penicillin Side-Reactions, with Particular Reference to Fatalities from Anaphylactic Shock","volume":"38","author":"Idsoe","year":"1968","journal-title":"Bull. World Health Organ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaip.2022.09.006","article-title":"The Evolution of Our Understanding of Penicillin Allergy: 1942\u20132022","volume":"11","author":"Macy","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaip.2019.11.035","article-title":"Adverse Reactions Associated with Penicillins, Carbapenems, Monobactams, and Clindamycin: A Retrospective Population-Based Study","volume":"8","author":"Liang","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jama.283.5.590-JMN0202-2-1","article-title":"Some Men Who Take Viagra Die\u2014Why?","volume":"283","author":"Mitka","year":"2000","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1097\/01.ju.0000125198.32936.38","article-title":"The Prevalence of Hypertension, Hyperlipidemia, Diabetes Mellitus and Depression in Men with Erectile Dysfunction","volume":"171","author":"Seftel","year":"2004","journal-title":"J. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2003.07.042","article-title":"Impaired Brachial Artery Endothelium-Dependent and -Independent Vasodilation in Men with Erectile Dysfunction and No Other Clinical Cardiovascular Disease","volume":"43","author":"Kaiser","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1185\/03007990802128781","article-title":"Integrating Evidence from Multiple Sources to Evaluate Post-Approval Safety: An Example of Sildenafil Citrate and Cardiovascular Events","volume":"24","author":"Sobel","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1743-6109.2011.02537.x","article-title":"10-Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type-5 Inhibitors","volume":"9","author":"Lowe","year":"2012","journal-title":"J. Sex. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1368-5031.2005.00578.x","article-title":"Past, Present, and Future: A 7-Year Update of Viagra\u00ae (Sildenafil Citrate): A 7-Year Update of Viagra\u00ae","volume":"59","author":"Jackson","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"ref_79","unstructured":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Board on Population Health and Public Health Practice, and Committee on Reproductive Health Services: Assessing the Safety and Quality of Abortion Care in the U.S (2018). The Safety and Quality of Abortion Care in the United States, National Academies Press (US)."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/gut.52.4.600","article-title":"Non-Steroidal Anti-Inflammatory Drugs: Overall Risks and Management. Complementary Roles for COX-2 Inhibitors and Proton Pump Inhibitors","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.aje.a117469","article-title":"Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Hospitalizations for Peptic Ulcer Disease in Elderly Persons","volume":"141","author":"Smalley","year":"1995","journal-title":"Am. J. Epidemiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/AOG.0000000000002212","article-title":"Safety of Medical Abortion Provided Through Telemedicine Compared With In Person","volume":"130","author":"Grossman","year":"2017","journal-title":"Obs. Gynecol"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1572-0241.2005.41833.x","article-title":"A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use","volume":"100","author":"Lanas","year":"2005","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"key":"ref_84","unstructured":"(2025, May 22). Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products\u2014Content and Format, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and."},{"key":"ref_85","unstructured":"(2025, May 22). MIFEPREX Prescriber\u2019s Agreement, Available online: https:\/\/www.fda.gov\/media\/164648\/download?attachment."},{"key":"ref_86","first-page":"233339282110689","article-title":"Mifepristone Adverse Events Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse Event Reporting System and Those Obtained Through the Freedom of Information Act","volume":"8","author":"Cirucci","year":"2021","journal-title":"Health Serv. Res. Manag. Epidemiol."},{"key":"ref_87","first-page":"3","article-title":"Deaths and Severe Adverse Events after the Use of Mifepristone as an Abortifacient from September 2000 to February 2019","volume":"36","author":"Aultman","year":"2021","journal-title":"Issues Law Med."},{"key":"ref_88","unstructured":"(2025, May 22). Mifepristone Is a Safe Choice. Available online: https:\/\/reproductivefreedomforall.org\/wp-content\/uploads\/2017\/01\/2.-Mifepristone-is-a-Safe-Choice.pdf."},{"key":"ref_89","unstructured":"(2025, May 22). ADVAIR DISKUS Prescribing Information. Available online: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Advair_Diskus\/pdf\/ADVAIR-DISKUS-PI-PIL-IFU.PDF."},{"key":"ref_90","unstructured":"(2025, May 22). XANAX Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018276s052lbl.pdf."},{"key":"ref_91","unstructured":"(2025, May 22). Mifepristone U.S. Postmarketing Adverse Events Summary through 04\/30\/2011. Available online: https:\/\/www.minnpost.com\/wp-content\/uploads\/sites\/default\/files\/attachments\/Mifeprex_April2011_AEs.pdf."},{"key":"ref_92","unstructured":"Public leadership Institute (2025, May 22). Abortion Is Health Care Resolution. Available online: https:\/\/publicleadershipinstitute.org\/abortion-rights\/abortion-health-care-resolution\/."},{"key":"ref_93","unstructured":"Missouri House of Representatives (2025, May 22). Concurrent Resolution No. 63 in the Second Regular Session of the 101st General Assembly, Available online: https:\/\/documents.house.mo.gov\/billtracking\/bills221\/hlrbillspdf\/5048H.01I.pdf."},{"key":"ref_94","unstructured":"Wisconsin Assembly (2025, May 22). Assembly Joint Resolution 10 of the 2017\u20132018 Legislature, Available online: https:\/\/docs.legis.wisconsin.gov\/2017\/related\/proposals\/ajr10."},{"key":"ref_95","unstructured":"(2025, May 22). Resolution No. 506 (Co-Sponsored C)\u2014Removing Risk Evaluation and Mitigation Strategy (REMS) Categorization on Mifepristone. Available online: https:\/\/www.reproductiveaccess.org\/wp-content\/uploads\/2019\/02\/Resolution-No.-506-REMS.pdf."},{"key":"ref_96","unstructured":"Boonstra, H. (2024). Medication Abortion Restrictions Burden Women and Providers\u2014And Threaten U.S. Trend Toward Very Early Abortion, Guttmacher Institute. Available online: https:\/\/www.guttmacher.org\/gpr\/2013\/03\/medication-abortion-restrictions-burden-women-and-providers-and-threaten-us-trend-toward."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2105\/AJPH.2012.301159","article-title":"Safety of Aspiration Abortion Performed by Nurse Practitioners, Certified Nurse Midwives, and Physician Assistants Under a California Legal Waiver","volume":"103","author":"Weitz","year":"2013","journal-title":"Am. J. Public Health"},{"key":"ref_98","unstructured":"(2025, May 22). Food and Drug Administration: Information on Mifeprex Labeling Changes and Ongoing Monitoring Efforts, Available online: https:\/\/www.gao.gov\/products\/gao-18-292."},{"key":"ref_99","unstructured":"Cavazzoni, P. (2025, May 22). Letter to Graham Chelius, M.D., The Society of Family Planning & The California Academy of Family Physicians. Available online: https:\/\/www.aclu.org\/sites\/default\/files\/field_document\/fda_letter_to_chelius.pdf."},{"key":"ref_100","unstructured":"(2025, May 22). Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation, Available online: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation."},{"key":"ref_101","unstructured":"(2025, May 22). Warning Letter to Aidaccess.Org, Available online: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/aidaccessorg-575658-03082019."},{"key":"ref_102","unstructured":"(2025, May 22). Warning Letter to Rablon, Available online: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/rablon-1111111-03082019."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2024.4266","article-title":"Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women\u2019s Health Organization Decision","volume":"331","author":"Aiken","year":"2024","journal-title":"JAMA"},{"key":"ref_104","unstructured":"Planned Parenthood (2025, May 22). I Took Abortion Pills. Will a Doctor Be Able to Tell That I Had an Abortion?. Available online: https:\/\/www.plannedparenthood.org\/blog\/i-took-abortion-pills-will-a-doctor-be-able-to-tell-that-i-had-an-abortion."},{"key":"ref_105","unstructured":"Safe2choose (2025, May 22). Will Medical Staff Be Able to Notice that I Am Having an Abortion?. Available online: https:\/\/safe2choose.org\/faq\/medical-abortion-faq\/during-abortion-with-pills\/will-medical-staff-be-able-to-notice-that-i-am-having-an-abortion."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Advancing Equity in Obstetric and Gynecologic Health Care (2024). ACOG Committee Statement No. 13: Self-Managed Abortion. Obstet. Gynecol., 144, e152.","DOI":"10.1097\/AOG.0000000000005755"}],"container-title":["BioTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-6284\/14\/2\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:38Z","timestamp":1760031578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-6284\/14\/2\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":106,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biotech14020039"],"URL":"https:\/\/doi.org\/10.3390\/biotech14020039","relation":{},"ISSN":["2673-6284"],"issn-type":[{"type":"electronic","value":"2673-6284"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}